BB Biotech AG announced today that it will be included in the SPI ESG Index of the SIX Swiss Exchange, effective September 22, 2025. This inclusion underscores the investment company's long-standing commitment to responsible investing and sustainable corporate governance.
Dr. Christian Koch, Head BB Biotech at Bellevue Asset Management, stated: "The inclusion in the SPI ESG Index is an important confirmation of our commitment to sustainability. It also underscores our strategic focus on biotechnology companies that create financial value while making an important contribution to society."
Launched in 2021, the SPI ESG Index includes companies from the Swiss Performance Index (SPI) that are selected by the independent sustainability agency Inrate based on strict criteria. This provides investors with a transparent benchmark for sustainable equity investments in Switzerland.
The inclusion enhances BB Biotech's visibility among ESG-oriented investors and underscores the long-term attractiveness of its portfolio. As one of the world's largest investors in innovative drug developers, BB Biotech's addition to the index signals the growing importance of environmental, social, and governance factors in the biotechnology sector.
For more information, visit the BB Biotech website or view the original release on NewMediaWire.
